Cargando…

Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations

Four COVID-19 vaccines are approved for use in Australia: Pfizer-BioNTech BNT162b2 (Comirnaty), AstraZeneca ChAdOx1 (Vaxzevria), Moderna mRNA-1273 (Spikevax) and Novavax NVX-CoV2373 (Nuvaxovid). We sought to examine adverse events following immunisation (AEFI) at days 3 and 42 after primary doses 1,...

Descripción completa

Detalles Bibliográficos
Autores principales: Salter, Sandra M., Li, Dani, Trentino, Kevin, Nissen, Lisa, Lee, Kenneth, Orlemann, Karin, Peters, Ian, Murray, Kevin, Leeb, Alan, Deng, Lucy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786585/
https://www.ncbi.nlm.nih.gov/pubmed/36560426
http://dx.doi.org/10.3390/vaccines10122017
_version_ 1784858321097850880
author Salter, Sandra M.
Li, Dani
Trentino, Kevin
Nissen, Lisa
Lee, Kenneth
Orlemann, Karin
Peters, Ian
Murray, Kevin
Leeb, Alan
Deng, Lucy
author_facet Salter, Sandra M.
Li, Dani
Trentino, Kevin
Nissen, Lisa
Lee, Kenneth
Orlemann, Karin
Peters, Ian
Murray, Kevin
Leeb, Alan
Deng, Lucy
author_sort Salter, Sandra M.
collection PubMed
description Four COVID-19 vaccines are approved for use in Australia: Pfizer-BioNTech BNT162b2 (Comirnaty), AstraZeneca ChAdOx1 (Vaxzevria), Moderna mRNA-1273 (Spikevax) and Novavax NVX-CoV2373 (Nuvaxovid). We sought to examine adverse events following immunisation (AEFI) at days 3 and 42 after primary doses 1, 2, 3 and booster. We conducted active vaccine safety surveillance from 130 community pharmacies in Australia integrated with AusVaxSafety, between August 2021–April 2022. Main outcomes: AEFI at 0–3 days post-vaccination; medical review/advice at 3 days and 42 days post-vaccination; SARS-CoV-2 breakthrough infection by day 42. Of 110,024 completed day 3 surveys (43.6% response rate), 50,367 (45.8%) reported any AEFI (highest proportions: Pfizer 42%, primary dose 3; AstraZeneca 58.3%, primary dose 1; Moderna 65.4% and Novavax 58.8%, both primary dose 2). The most common AEFI reported across all doses/vaccines were local reactions, systemic aches and fatigue/tiredness. Overall, 2172/110,024 (2.0%) and 1182/55,329 (2.1%) respondents sought medical review at days 3 and 42, respectively, and 931/42,318 (2.2%) reported breakthrough SARS-CoV-2 infection at day 42. We identified similar AEFI profiles but at lower proportions than previously reported for Pfizer, AstraZeneca, Moderna and Novavax COVID-19 vaccines. Moderna vaccine was the most reactogenic and associated with higher AEFI proportions across primary doses 2, 3, and booster.
format Online
Article
Text
id pubmed-9786585
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97865852022-12-24 Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations Salter, Sandra M. Li, Dani Trentino, Kevin Nissen, Lisa Lee, Kenneth Orlemann, Karin Peters, Ian Murray, Kevin Leeb, Alan Deng, Lucy Vaccines (Basel) Article Four COVID-19 vaccines are approved for use in Australia: Pfizer-BioNTech BNT162b2 (Comirnaty), AstraZeneca ChAdOx1 (Vaxzevria), Moderna mRNA-1273 (Spikevax) and Novavax NVX-CoV2373 (Nuvaxovid). We sought to examine adverse events following immunisation (AEFI) at days 3 and 42 after primary doses 1, 2, 3 and booster. We conducted active vaccine safety surveillance from 130 community pharmacies in Australia integrated with AusVaxSafety, between August 2021–April 2022. Main outcomes: AEFI at 0–3 days post-vaccination; medical review/advice at 3 days and 42 days post-vaccination; SARS-CoV-2 breakthrough infection by day 42. Of 110,024 completed day 3 surveys (43.6% response rate), 50,367 (45.8%) reported any AEFI (highest proportions: Pfizer 42%, primary dose 3; AstraZeneca 58.3%, primary dose 1; Moderna 65.4% and Novavax 58.8%, both primary dose 2). The most common AEFI reported across all doses/vaccines were local reactions, systemic aches and fatigue/tiredness. Overall, 2172/110,024 (2.0%) and 1182/55,329 (2.1%) respondents sought medical review at days 3 and 42, respectively, and 931/42,318 (2.2%) reported breakthrough SARS-CoV-2 infection at day 42. We identified similar AEFI profiles but at lower proportions than previously reported for Pfizer, AstraZeneca, Moderna and Novavax COVID-19 vaccines. Moderna vaccine was the most reactogenic and associated with higher AEFI proportions across primary doses 2, 3, and booster. MDPI 2022-11-25 /pmc/articles/PMC9786585/ /pubmed/36560426 http://dx.doi.org/10.3390/vaccines10122017 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Salter, Sandra M.
Li, Dani
Trentino, Kevin
Nissen, Lisa
Lee, Kenneth
Orlemann, Karin
Peters, Ian
Murray, Kevin
Leeb, Alan
Deng, Lucy
Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations
title Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations
title_full Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations
title_fullStr Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations
title_full_unstemmed Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations
title_short Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations
title_sort safety of four covid-19 vaccines across primary doses 1, 2, 3 and booster: a prospective cohort study of australian community pharmacy vaccinations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786585/
https://www.ncbi.nlm.nih.gov/pubmed/36560426
http://dx.doi.org/10.3390/vaccines10122017
work_keys_str_mv AT saltersandram safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations
AT lidani safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations
AT trentinokevin safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations
AT nissenlisa safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations
AT leekenneth safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations
AT orlemannkarin safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations
AT petersian safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations
AT murraykevin safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations
AT leebalan safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations
AT denglucy safetyoffourcovid19vaccinesacrossprimarydoses123andboosteraprospectivecohortstudyofaustraliancommunitypharmacyvaccinations